Results and Key Takeaways from the Final OS Analysis of the CLEOPATRA Study
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study.
Clinical Pearls
Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses results and key takeaways from the final overall survival (OS) analysis of the CLEOPATRA study. This study looked at first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
- Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm – a different of 15.7 months.
- The standard first line treatment for patients with HER2-positive metastatic breast cancer should be pertuzumab, trastuzumab, and a taxane.
- In practice, community oncologists could use paclitaxel instead of docetaxel.
<<<
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
